Wolters Kluwer Health announces completion of Pharmacy OneSource acquisition

Wolters Kluwer Health, a leading provider of information and business intelligence for professionals, students and institutions in medicine, nursing, allied health and pharmacy, today announced it has completed the acquisition of Pharmacy OneSource, a leading Software-as-a-Service (SaaS) provider in the hospital pharmacy market. The agreement to acquire Pharmacy OneSource was announced on November 29, 2010.

This acquisition extends Wolters Kluwer Health's Clinical Decision Support (CDS) solutions into the hospital pharmacy market and fits squarely into the company's strategy to expand its business into high growth markets, particularly the fast-growing point-of-care market.

"The acquisition of Pharmacy OneSource will further drive our growth in the point-of-care market, which includes the critical area of the hospital pharmacy," said Arvind Subramanian, President & CEO, Wolters Kluwer Health Clinical Solutions. "Our combined product offerings will give us an excellent portfolio of healthcare information and clinical decision tools for the pharmacy, where there is a strong need for resources and tools to drive compliance, greater patient safety and cost reductions."

Terms of the acquisition were not disclosed.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine